UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 67

Sortiert nach

Osteoporosis and Fracture Risk in Women of Different Ethnic Groups

Journal of bone and mineral research, 2005-02, Vol.20 (2), p.185-194

2005

Volltextzugriff (PDF)

Evaluating Atypical Features of Femur Fractures: How Change in Radiological Criteria Influenced Incidence and Demography of Atypical Femur Fractures in a Community Setting

Journal of bone and mineral research, 2017-11, Vol.32 (11), p.2304-2314

2017

Volltextzugriff (PDF)

Open-label study of treatment with alendronate sodium plus vitamin D in men and women with osteoporosis in Thailand

BMC musculoskeletal disorders, 2018-11, Vol.19 (1), p.392-392, Article 392

2018

Volltextzugriff (PDF)

History of alendronate

Bone (New York, N.Y.), 2020-08, Vol.137, p.115411-115411, Article 115411

2020

Volltextzugriff (PDF)

In Vitro and In Vivo Responses to High and Low Doses of Nitrogen-Containing Bisphosphonates Suggest Engagement of Different Mechanisms for Inhibition of Osteoclastic Bone Resorption

Calcified tissue international, 2013-06, Vol.92 (6), p.531-538

2013

Volltextzugriff (PDF)

Effect of alendronate and vitamin D3 on fractional calcium absorption in a double‐blind, randomized, placebo‐controlled trial in postmenopausal osteoporotic women

Journal of bone and mineral research, 2011-08, Vol.26 (8), p.1836-1844

2011

Volltextzugriff (PDF)

Oral daily PTH(1-34) tablets (EB613) in postmenopausal women with low BMD or osteoporosis: a randomized, placebo-controlled, 6-month, phase 2 study

Journal of bone and mineral research, 2024-07, Vol.39 (6), p.672-682

2024

Volltextzugriff (PDF)

Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis

The New England journal of medicine, 1995-11, Vol.333 (22), p.1437-1444

1995

Volltextzugriff (PDF)

Odanacatib, a cathepsin‐K inhibitor for osteoporosis: A two‐year study in postmenopausal women with low bone density

Journal of bone and mineral research, 2010-05, Vol.25 (5), p.937-947

2010

Volltextzugriff (PDF)

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three‐year continued therapy and resolution of effect

Journal of bone and mineral research, 2011-02, Vol.26 (2), p.242-251

2011

Volltextzugriff (PDF)

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

JAMA : the journal of the American Medical Association, 2006-12, Vol.296 (24), p.2927

2006

Volltextzugriff (PDF)

Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women

The New England journal of medicine, 2004-03, Vol.350 (12), p.1189-1199

2004

Volltextzugriff (PDF)

Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment

JAMA : the journal of the American Medical Association, 2001-12, Vol.286 (22), p.2815

2001

Volltextzugriff (PDF)

Changes in bone density and turnover after alendronate or estrogen withdrawal

Menopause (New York, N.Y.), 2004-11, Vol.11 (6, Part 1 of 2), p.622-630

2004

Volltextzugriff (PDF)

Vitamin D Binding Protein and Vitamin D Levels

International Journal of Endocrinology, 2014-01, Vol.2014, p.638263-2

2014

Volltextzugriff (PDF)

Prevention of Postmenopausal Bone Loss: Six-Year Results from the Early Postmenopausal Intervention Cohort Study

The journal of clinical endocrinology and metabolism, 2004-10, Vol.89 (10), p.4879-4885

2004

Volltextzugriff (PDF)

Randomized Trial of Effect of Alendronate Continuation Versus Discontinuation in Women With Low BMD: Results From the Fracture Intervention Trial Long‐Term Extension

Journal of bone and mineral research, 2004-08, Vol.19 (8), p.1259-1269

2004

Volltextzugriff (PDF)

Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study

Journal of bone and mineral metabolism, 2005-08, Vol.23 (5), p.382-388

2005

Volltextzugriff (PDF)

Prediction of Fracture Risk in Postmenopausal White Women With Peripheral Bone Densitometry: Evidence From the National Osteoporosis Risk Assessment

Journal of bone and mineral research, 2002-12, Vol.17 (12), p.2222-2230

2002

Volltextzugriff (PDF)

Use of Bone Alkaline Phosphatase to Monitor Alendronate Therapy in Individual Postmenopausal Osteoporotic Women

Clinical chemistry (Baltimore, Md.), 1999-07, Vol.45 (7), p.1009-1017

1999

Volltextzugriff (PDF)

Skeletal benefits of alendronate : 7-year treatment of postmenopausal osteoporotic women

The journal of clinical endocrinology and metabolism, 2000-09, Vol.85 (9), p.3109-3115

2000

Volltextzugriff (PDF)

Prevalent Vertebral Deformities Predict Mortality and Hospitalization in Older Women with Low Bone Mass

Journal of the American Geriatrics Society (JAGS), 2000-03, Vol.48 (3), p.241-249

2000

Volltextzugriff (PDF)

Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: Results from the 24-week extension of a 15-week randomized, controlled trial

Bone (New York, N.Y.), 2009-04, Vol.44 (4), p.639-647

2009

Volltextzugriff (PDF)

Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study

Current medical research and opinion, 2003, Vol.19 (5), p.383-394

2003

Volltextzugriff (PDF)

Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study

Menopause (New York, N.Y.), 2003-09, Vol.10 (5), p.412-419

2003

Volltextzugriff (PDF)

1 – 25 von 67

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(66)
Mit Volltextzugriff
(63)

Publikationsform

Artikel
(66)
Buchkapitel
(1)

Sprache

Englisch
(67)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Science & Technology
(41)
Life Sciences & Biomedicine
(40)
Humans
(34)
Female
(33)
Biological And Medical Sciences
(28)
Aged
(26)
Middle Aged
(25)
Endocrinology & Metabolism
(22)
Osteoporosis
(22)
Medical Sciences
(21)
Bone Density
(18)
Osteoporosis, Postmenopausal - Drug Therapy
(18)
General & Internal Medicine
(16)
Alendronate - Administration & Dosage
(14)
Double-Blind Method
(14)
Medicine, General & Internal
(14)
Alendronate
(13)
Bone Density - Drug Effects
(13)
Aged, 80 And Over
(12)
Alendronate - Therapeutic Use
(12)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Osteoporosis and Fracture Risk in Women of Different Ethnic Groups

Evaluating Atypical Features of Femur Fractures: How Change in Radiological Criteria Influenced Incidence and Demography of Atypical Femur Fractures in a Community Setting

Open-label study of treatment with alendronate sodium plus vitamin D in men and women with osteoporosis in Thailand

History of alendronate

In Vitro and In Vivo Responses to High and Low Doses of Nitrogen-Containing Bisphosphonates Suggest Engagement of Different Mechanisms for Inhibition of Osteoclastic Bone Resorption

Effect of alendronate and vitamin D3 on fractional calcium absorption in a double‐blind, randomized, placebo‐controlled trial in postmenopausal osteoporotic women

Oral daily PTH(1-34) tablets (EB613) in postmenopausal women with low BMD or osteoporosis: a randomized, placebo-controlled, 6-month, phase 2 study

Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis

Odanacatib, a cathepsin‐K inhibitor for osteoporosis: A two‐year study in postmenopausal women with low bone density

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three‐year continued therapy and resolution of effect

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women

Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment

Changes in bone density and turnover after alendronate or estrogen withdrawal

Vitamin D Binding Protein and Vitamin D Levels

Prevention of Postmenopausal Bone Loss: Six-Year Results from the Early Postmenopausal Intervention Cohort Study

Randomized Trial of Effect of Alendronate Continuation Versus Discontinuation in Women With Low BMD: Results From the Fracture Intervention Trial Long‐Term Extension

Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study

Prediction of Fracture Risk in Postmenopausal White Women With Peripheral Bone Densitometry: Evidence From the National Osteoporosis Risk Assessment

Use of Bone Alkaline Phosphatase to Monitor Alendronate Therapy in Individual Postmenopausal Osteoporotic Women

Skeletal benefits of alendronate : 7-year treatment of postmenopausal osteoporotic women

Prevalent Vertebral Deformities Predict Mortality and Hospitalization in Older Women with Low Bone Mass

Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: Results from the 24-week extension of a 15-week randomized, controlled trial

Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study

Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study

Suchergebnisse filtern